EW
55
-2
K
54
-2
FLS
61
-3
MSFT
54
-3
NAVI
35
-5
NWS
64
-9
KMI
71
-2
PAYX
45
-9
MMM
35
-5
CL
47
-3
ALLE
25
-3
ROST
63
-3
HST
52
-6
DE
48
-2
AEE
53
-3
GT
47
-2
MS
69
-3
PPL
44
-3
CHD
34
-5
KR
50
-2
EW
55
-2
K
54
-2
FLS
61
-3
MSFT
54
-3
NAVI
35
-5
NWS
64
-9
KMI
71
-2
PAYX
45
-9
MMM
35
-5
CL
47
-3
ALLE
25
-3
ROST
63
-3
HST
52
-6
DE
48
-2
AEE
53
-3
GT
47
-2
MS
69
-3
PPL
44
-3
CHD
34
-5
KR
50
-2
Financhill
Back

Aadi Bioscience 10K Form

Buy
52

AADI
Aadi Bioscience

Last Price:
$3.19
Seasonality Move:
-10.43%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AADI News And Ratings

See the #1 stock for the next 7 days that we like better than AADI

AADI Financial Statistics

Sales & Book Value

Annual Sales: $24.4M
Cash Flow: $-15.9M
Price / Cash Flow: 0
Annual Sales: $2.80
Price / Book: 1.15

Profitability

EPS (TTM): -2.28000
Net Income (TTM): $-61.7M
Gross Margin: $21.5M
Return on Equity: -66.83%
Return on Assets: -54.07%

Aadi Bioscience Earnings Forecast

Key Aadi Bioscience Financial Ratios

  • The Gross Profit Margin over the past 3 years for AADI is 88.47%.
  • The Selling, General & Administrative Expenses for AADI have been equal to 182.92% of Gross Profit Margin.
  • The Research & Development expenses have been 200.91% of Revenue.
  • The Interest Expense is -0.35% of Operating Income.
  • The Net Earning history of AADI is -270.04% of Total Revenues.
  • Per Share Earnings over the last 4 years have been positive in 2 years.

Aadi Bioscience Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AADI
Website: aadibio.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.89
Quick Ratio: 4.37

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AADI Technical Analysis vs Fundamental Analysis

Buy
52
Aadi Bioscience (AADI) is a Buy

Is Aadi Bioscience a Buy or a Sell?

  • Aadi Bioscience stock is rated a Buy
    The current Aadi Bioscience [AADI] share price is $3.21. The Score for AADI is 52, which is 4% above its historic median score of 50, and infers lower risk than normal.